Search results for "risk factor"

showing 10 items of 4321 documents

Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables

2012

The aim of the study was to identify predictors associated with a lower likelihood of achieving a clinical remission 1 year after the first break of the illness. Participants were 174 consecutive subjects included in a first episode programme with no prior treatment with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone in a randomized, open-label, prospective clinical trial. The main outcome variable was the remission criteria developed by the Remission in Schizophrenia Working Group. Clinical variables were included in a logistic regression analysis in order to predict the remission state at 1 year. At 1 year, 31% of patients met criteria for remis…

AdultMaleOlanzapinePediatricsmedicine.medical_specialtymedicine.medical_treatmentLogistic regressionSeverity of Illness IndexTime-to-TreatmentBenzodiazepinesYoung AdultRisk FactorsmedicineHumansLongitudinal StudiesAntipsychoticPsychiatryBiological PsychiatryFirst episodeRisperidoneRemission InductionPrognosisRisperidonemedicine.diseaseClinical trialPsychiatry and Mental healthLogistic ModelsPsychotic DisordersOlanzapineSchizophreniadupSchizophreniaEducational StatusHaloperidolFemaleSchizophrenic PsychologyPsychologyAntipsychotic Agentsmedicine.drugPsychiatry Research
researchProduct

Small renal cell carcinomas – How dangerous are they really? Results of a large multicenter study

2013

Modern diagnostic ultrasound and cross-sectional imaging has enabled the detection of increasing numbers of renal tumours. The aim of this study was to investigate the tumour- and patient-specific characteristics and prognosis of small renal cell carcinomas (RCCs) after surgical resection.The study included 2197 patients who underwent surgical resection of histologically confirmed RCC ⩽ 4 cm between 1990 and 2011. Median (mean) follow-up was 56.2 (65.5) months.At the time of surgery, tumours were staged as pT ⩾ 3a in 175 (8.0%) cases, 134 (6.2%) were poorly differentiated and 75 (3.5%) were metastasised. The larger the tumour size, the higher was the risk of presenting with stage pT ⩾ 3a (p…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAdolescentCellNephrectomyGastroenterologyMetastasisYoung AdultInternal medicinemedicineHumansStage (cooking)Risk factorCarcinoma Renal CellPathologicalAgedNeoplasm StagingAged 80 and overbusiness.industryMortality rateMiddle Agedmedicine.diseaseSurvival AnalysisKidney NeoplasmsTumor Burdenmedicine.anatomical_structureOncologyMulticenter studyFemalebusinessKidney cancerFollow-Up StudiesEuropean Journal of Cancer
researchProduct

Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project

2014

Background: Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes. The etiology of NHL is incompletely understood, and increasing evidence suggests that risk factors may vary by NHL subtype. However, small numbers of cases have made investigation of subtype-specific risks challenging. The International Lymphoma Epidemiology Consortium therefore undertook the NHL Subtypes Project, an international collaborative effort to investigate the etiologies of NHL subtypes. This article describes in detail the project rationale and design. Methods: We pooled individual-level data from 20 case-control studies (17 471 NHL cases, 23 096 controls) from North Ame…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAdolescentChronic lymphocytic leukemiaFollicular lymphomaNon-Hodgkin lymphoma (NHL)ArticleLymphoplasmacytic LymphomaYoung AdultRisk Factorsimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiology of cancerPrevalencemedicineHumansAgedAged 80 and overMycosis fungoidesbusiness.industryLymphoma Non-HodgkinAustraliaWaldenstrom macroglobulinemiaGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaEuropeOncologyCase-Control StudiesEpidemiologic Research DesignNorth AmericaImmunologyInternational Lymphoma Epidemiology Consortiumhematologic malignancyFemaleMantle cell lymphomabusinessJNCI Monographs
researchProduct

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylatin…

2018

Patients with primary refractory or relapsed-acute myeloid leukemia (RR-AML), particularly older adults, have dismal outcomes and limited therapy options [1]. Given the tolerability of hypomethylat...

AdultMaleOncologyCancer Researchmedicine.medical_specialtyMyeloidAdolescentendocrine system diseasesmedicine.medical_treatmentHematopoietic stem cell transplantationRisk AssessmentYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTransplantation HomologousneoplasmsSurvival analysisAgedRetrospective StudiesAged 80 and overbusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisTransplantationLeukemia Myeloid AcuteLeukemiaTreatment Outcomemedicine.anatomical_structureOncologyTolerabilityHypomethylating agentDrug Resistance Neoplasmhypomethylating agent acute myeloid leukemia.FemaleNeoplasm Recurrence LocalbusinessLeukemia & Lymphoma
researchProduct

Medical exposure to ionising radiation and the risk of brain tumours: Interphone study group, Germany

2007

Abstract Background The role of exposure to low doses of ionising radiation in the aetiology of brain tumours has yet to be clarified. The objective of this study was to investigate the association between medically or occupationally related exposure to ionising radiation and brain tumours. Methods We used self-reported medical and occupational data collected during the German part of a multinational case–control study on mobile phone use and the risk of brain tumours (Interphone study) for the analyses. Results For any exposure to medical ionising radiation we found odds ratios (ORs) of 0.63 (95% confidence interval (CI) = 0.48–0.83), 1.08 (95% CI = 0.80–1.45) and 0.97 (95% CI = 0.54–1.75)…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyNeoplasms Radiation-Inducedaetiologymedicine.medical_treatmentcase-control studyAcoustic neuromaMeningiomaElectromagnetic FieldsGermanyOccupational ExposureRadiation IonizingInternal medicineGliomaEpidemiologyotorhinolaryngologic diseasesmedicineHumansrisk factorsRisk factorAgedBrain Neoplasmsbusiness.industryionising radiationbrain tumoursCase-control studyOdds ratioMiddle Agedmedicine.diseaseRadiation therapyOncologyCase-Control StudiesFemaleepidemiologybusinessNuclear medicineCell Phone
researchProduct

Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries

2015

We aimed at investigating the distribution and risk of all second discordant primary cancers (SDPCs) after a specific first primary cancer in Germany and Sweden to provide etiological understanding of SDPCs and insight into their incidence rates and recording practices. Among 1,537,004 survivors of first primary cancers in Germany and 588,103 in Sweden, overall 80,162 and 32,544 SDPCs were recorded, respectively. Standardized incidence ratios (SIRs) of all SDPCs were elevated at levels between 1.1 and 2.1 after 23 (out of overall 29) cancers in Germany and at levels between 1.1 and 1.6 after 24 cancers in Sweden, and among them, elevated SIRs were found after 19 cancers in both populations.…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyPediatricsPoor prognosisAdolescentDisease-Free SurvivalYoung AdultRisk FactorsGermanyInternal medicinemedicineHumansRegistriesAge of OnsetYoung adultAgedAged 80 and overSwedenbusiness.industryIncidenceIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle AgedPrimary cancermedicine.diseasehumanitiesCancer registryOncologyEtiologyFemaleAge of onsetbusinessCancer Letters
researchProduct

Factors affecting recurrence and progression in superficial bladder tumours

1995

Prognostic factors in superficial bladder tumours are highly correlated with each other. In this study, their relative importance is examined and grouping of patients in three different prognostic groups suggested. 576 patients (from EORTC protocols 30790 and 30782) were analysed. They have been followed from 3 months to 8.6 years with a median of 4 years. 76 patients developed an invasive tumour (or = T2); the shortest time to invasion was 12 weeks, the longest was 6.6 years. Time from invasion to death ranged from 3 weeks to 4.4 years with a median of 2 years. Prognostic factors contributing to recurrence, invasion and survival were investigated: age, sex, size of largest tumour, number o…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyTime FactorsMultivariate analysisAdolescentMalignant diseaseRisk groupsRisk FactorsInternal medicinemedicineCarcinomaHumansNeoplasm InvasivenessIn patientSurvival rateAgedAged 80 and overAnalysis of VarianceCarcinoma Transitional Cellbusiness.industryMiddle AgedPrognosismedicine.diseaseSurgerySurvival RateTransitional cell carcinomaUrinary Bladder NeoplasmsOncologyTumour sizeDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesEuropean Journal of Cancer
researchProduct

High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability.

2007

Mutation screening of the BRCA1 and BRCA2 genes in probands with familial breast/ovarian cancer has been greatly improved by the multiplex ligation-dependent probe amplification (MLPA) assay able to evidence gene rearrangements not detectable by standard screening methods. However, no criteria for selection of cases to be submitted to the MLPA test have been reported yet. We used the BRCAPro software for the selection of familial breast/ovarian cancer probands investigated with the MLPA approach after negative BRCA1/2 conventional mutation screening. One hundred and seventy-seven probands were investigated for germline BRCA1/2 mutations after assessment of genetic risk using BRCAPro. Proban…

AdultMaleOncologyProbandcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyendocrine system diseasesBreast NeoplasmsGermlineBreast Neoplasms MaleGermline mutationBreast cancerRisk FactorsInternal medicinePrevalenceHumansMedicineGenetic Predisposition to DiseaseMultiplexMultiplex ligation-dependent probe amplificationskin and connective tissue diseasesAgedSequence DeletionOvarian NeoplasmsGeneticsBRCA1 Proteinbusiness.industryGenetic Carrier ScreeningProstatic NeoplasmsHematologyMiddle Agedmedicine.diseaseBRCA1 BRCA2 BRCAPro breast cancer MLPA ovarian cancerPedigreeOncologyMutation (genetic algorithm)FemalebusinessOvarian cancerSoftware
researchProduct

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin

2017

<b><i>Objectives:</i></b> Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, in patients with soft-tissue sarcoma (STS). We evaluated the role of BMI as a risk factor for trabectedin-related toxicity in patients with STS. <b><i>Methods:</i></b> Data from 51 patients with metastatic/advanced STS treated with trabectedin after progression on ≥1 anthracycline ± ifosfamide regimen were retrospe…

AdultMaleOncologySarcopeniaCancer Researchmedicine.medical_specialtyNeutropeniaDioxolesNeutropeniaBody Mass Index03 medical and health sciences0302 clinical medicineThinnessRisk FactorsTetrahydroisoquinolinesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesIfosfamide030212 general & internal medicineRisk factorAntineoplastic Agents AlkylatingTrabectedinAgedRetrospective StudiesAged 80 and overIfosfamideToxicitybusiness.industrySoft tissue sarcomanutritional and metabolic diseasesSarcomaGeneral MedicineMiddle Agedmedicine.diseaseOncology030220 oncology & carcinogenesisSoft-tissue sarcomaFemaleUnderweightmedicine.symptombusinessBody mass indexFebrile neutropeniaTrabectedinmedicine.drugOncology
researchProduct

Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: The InterLymph…

2014

Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are two subtypes of non-Hodgkin lymphoma. A number of studies have evaluated associations between risk factors and CLL/SLL risk. However, these associations remain inconsistent or lacked confirmation. This may be due, in part, to the inadequate sample size of CLL/SLL cases. Methods: We performed a pooled analysis of 2440 CLL/SLL cases and 15 186 controls from 13 case-control studies from Europe, North America, and Australia. We evaluated associations of medical history, family history, lifestyle, and occupational risk factors with CLL/SLL risk. Multivariate logistic regression analyses were used to estimate …

AdultMaleOncologymedicine.medical_specialtyCancer ResearchChronic lymphocytic leukemiaComorbidityArticleYoung AdultRisk FactorsOccupational ExposureInternal medicinehemic and lymphatic diseasesOdds RatiomedicineHumansMedical historyFamily historyYoung adultLife StyleAgedAged 80 and overbusiness.industryAustraliaCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellLymphomaEuropeOncologyCase-Control StudiesMeta-analysisNorth AmericaImmunologyFemalebusiness
researchProduct